Patents by Inventor Daigo Inoyama

Daigo Inoyama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230271952
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Application
    Filed: May 5, 2023
    Publication date: August 31, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Masaki ASADA, Anatoly RUVINSKY, Yan ZHANG, Hidenori TAKAHASHI, Goran KRILOV, Daigo INOYAMA, Kyle KONZE, Mats SVENSSON
  • Compound having KDM5 inhibitory activity and pharmaceutical use thereof
    Patent number: 11691968
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: July 4, 2023
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito Kakuuchi, Shuhei Umemura, Masaki Asada, Anatoly Ruvinsky, Yan Zhang, Hidenori Takahashi, Goran Krilov, Daigo Inoyama, Kyle Konze, Mats Svensson
  • COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230109293
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Application
    Filed: October 24, 2022
    Publication date: April 6, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Masaki ASADA, Anatoly RUVINSKY, Yan ZHANG, Hidenori TAKAHASHI, Goran KRILOV, Daigo INOYAMA, Kyle KONZE, Mats SVENSSON
  • COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF
    Publication number: 20220289751
    Abstract: The compound disclosed is a KDM5 inhibitor represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
    Type: Application
    Filed: July 16, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Mats SVENSSON, Anatoly RUVINSKY, Daigo INOYAMA, Goran KRILOV, Hidenori TAKAHASHI, Kyle KONZE, Andreas VERRAS, Simon CRUMPLER, Maelle VALLADE, Calum MACLEOD, James N. SANDERSON, Richard J. BULL, Simon GAINES
  • HTS fluorescence polarization assay for inhibitors of Keap1-Nrf2 interaction
    Patent number: 9075070
    Abstract: Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: July 7, 2015
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Daigo Inoyama
  • HTS Fluorescence Polarization Assay for Inhibitors of Keap1-Nrf2 Interaction
    Publication number: 20120202298
    Abstract: Disclosed are methods and kits for identifying modulators of the Keap1-Nrf2-ARE pathway. In particular, a high throughput fluorescent polarization assay is described that identifies small molecules that inhibit the binding of a fluorescently labeled Nrf2 peptide with the kelch domain of the Keap1 protein. Also provided are probes that can be used in the described fluorescent polarization assay. The small molecules identified using the described assay are useful for combating oxidative stress-related disorders, such as those associated with cancer, emphysema, Huntington's disease, light-induced retinal damage, and stroke.
    Type: Application
    Filed: February 9, 2012
    Publication date: August 9, 2012
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Longqin Hu, Daigo Inoyama